Home » GLAXO SIGNS ANTIGEN DEAL TO BOOST CANCER VACCINES

GLAXO SIGNS ANTIGEN DEAL TO BOOST CANCER VACCINES

June 5, 2006

GlaxoSmithKline Plc has signed a deal to licence in a substantial portfolio of tumour-specific antigens from the international Ludwig Institute for Cancer Research to boost its cancer vaccine portfolio.
The Scotsman

KEYWORDS FDAnews Drug Daily Bulletin

08Feb
Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions
09Feb
The Inextricable Link Between Data Integrity and Quality Culture
15Feb
Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis
16Feb
Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success
22Feb
Best Practices for Developing and Maintaining a GxP Training Matrix
07Mar
FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

GLAXO SIGNS ANTIGEN DEAL TO BOOST CANCER VACCINES

Upcoming Events

Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

The Inextricable Link Between Data Integrity and Quality Culture

Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

Best Practices for Developing and Maintaining a GxP Training Matrix

FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

Consortium Gets EU Funding to Develop Continuous Blood Pressure Monitoring Device

FDA Approves GSK’s Oral Drug for Chronic Kidney Disease-Related Anemia

Aspivix’s Carevix Cleared to Reduce Pain, Bleeding in Gynecological Procedures

FDA Warns That Energy Supplement Contains Active Cialis Ingredient

The Revised ICH E8: A Guide to New Clinical Trial Requirements